Advertisement
News
Advertisement

Brigham and Women's cuts back on anti-clotting trial

Mon, 01/17/2011 - 8:46am
Mass High Tech: The Journal of New England Technology

Brigham and Women’s Hospital and Duke Clinical Research Institute have reduced the scope of two large-scale Phase 3 trials evaluating investigational anti-clotting medication vorapaxar.

The two institutions said in a press release that they are making the move in response to recommendations by the independent Data Safety Monitoring Board.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading